How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Continuous Renal Replacement Therapy Market
- By Modality: Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodialysis (CVVHD), Continuous Venovenous Hemodiafiltration (CVVHDF), Slow Continuous Ultrafiltration (SCUF)
- By Product Type: Hemofilters, Dialyzers, Replacement Fluids, Anticoagulants, CRRT Machines
- By End User: Hospitals, Dialysis Centers, Ambulatory Care Centers, Specialty Clinics
- By Application: Acute Kidney Injury (AKI), Sepsis-associated AKI, Chronic Kidney Disease (CKD) with Acute Exacerbation, Multi-organ Failure
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Continuous Venovenous Hemofiltration (CVVH) leads By Modality at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.164 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.172 →
Full report · locked preview
Everything inside the Continuous Renal Replacement Therapy Market report
A complete, evidence-based study - 11 chapters and 116 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Modality 4
Product Type 5
End User 4
Application 4
Companies profiled
Baxter International Inc.
Fresenius Medical Care AG & Co. KGaA
B. Braun Melsungen AG
Nipro Corporation
Asahi Kasei Corporation
NxStage Medical
Inc. (a Fresenius Medical Care company)
Medtronic plc
Toray Industries Inc.
Gambro (a part of Baxter)
Hospal Industrie
Nikkiso Co. Ltd.
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Baxter International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Fresenius Medical Care AG & Co. KGaA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →B. Braun Melsungen AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Nipro Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Asahi Kasei Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →NxStage Medical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Inc. (a Fresenius Medical Care company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Medtronic plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Toray Industries Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Gambro (a part of Baxter)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Hospal Industrie
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Nikkiso Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Outset Medical Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Hemocleanse
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →RenalSense Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Bellco S.r.l.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,641M by 2033 · 6.5% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Continuous Venovenous Hemofiltration (CVVH)53.1
- Continuous Venovenous Hemodialysis (CVVHD)13.1
- Continuous Venovenous Hemodiafiltration (CVVHDF)20.0
- Slow Continuous Ultrafiltration (SCUF)13.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,324M → $2,028M · 5.5%
Europe$922.6M → $1,602M · 7.1%
Asia Pacific$842.4M → $1,369M · 6.3%
Latin America$521.5M → $900.8M · 7.1%
Middle East and Africa$401.1M → $674.6M · 6.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.462026
6.462027
6.482028
6.502029
6.502030
6.522031
6.522032
6.532033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Baxter International Inc.23.8
- Fresenius Medical Care AG & Co. KGaA11.5
- B. Braun Melsungen AG11.6
- Nipro Corporation8.3
- Asahi Kasei Corporation6.8
- NxStage Medical10.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Modality32.4%
Product Type20.8%
End User17.2%
Application29.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America30.9
- Europe24.4
- Asia Pacific20.8
- Latin America13.7
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Baxter International Inc. | 82 | 97 | 92 | 79 | 74 | 87 | 85 |
| Fresenius Medical Care AG & Co. KGaA | 81 | 78 | 86 | 78 | 93 | 74 | 82 |
| B. Braun Melsungen AG | 74 | 81 | 69 | 62 | 78 | 66 | 72 |
| Nipro Corporation | 72 | 58 | 57 | 75 | 62 | 76 | 67 |
| Asahi Kasei Corporation | 68 | 63 | 60 | 54 | 75 | 64 | 64 |
| NxStage Medical | 70 | 58 | 70 | 62 | 71 | 60 | 65 |
| Inc. (a Fresenius Medical Care company) | 49 | 46 | 47 | 42 | 40 | 45 | 45 |
| Medtronic plc | 52 | 60 | 42 | 55 | 44 | 50 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Baxter International Inc.
- Fresenius Medical Care AG & Co. KGaA
- B. Braun Melsungen AG
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Baxter International Inc. | ✓ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Fresenius Medical Care AG & Co. KGaA | ◐ | ✓ | ◐ | ✓ | ✓ | ◐ |
| B. Braun Melsungen AG | ✓ | ◐ | − | − | ◐ | ◐ |
| Nipro Corporation | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Asahi Kasei Corporation | ✓ | ◐ | ✓ | − | ✓ | − |
| NxStage Medical | ✓ | − | ✓ | ◐ | ◐ | − |
| Inc. (a Fresenius Medical Care company) | − | ◐ | − | ◐ | − | − |
| Medtronic plc | ◐ | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Baxter International Inc.85
2Fresenius Medical Care AG & Co. KGaA82
3B. Braun Melsungen AG72
4Nipro Corporation67
5NxStage Medical65
6Asahi Kasei Corporation64
7Medtronic plc51
8Inc. (a Fresenius Medical Care company)45
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Baxter International Inc.Fresenius Medical Care AG & Co. KGaA
Challenger2
Strong scale, closing on the leaders.
B. Braun Melsungen AGNipro Corporation
Contender2
Focused players with pockets of strength.
Asahi Kasei CorporationNxStage Medical
Niche2
Specialists in a single segment or region.
Inc. (a Fresenius Medical Care company)Medtronic plc
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Modality in North America, then scale across Continuous Renal Replacement Therapy Market — a $553M beachhead inside a $8.90B market.
Beachhead (SOM)$553Mobtainable near-term
Serviceable (SAM)$3.35Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Continuous Venovenous Hemofiltration (CVVH)
Best fit — highest urgency & budget in Modality.
Economic buyer78 fit
Continuous Venovenous Hemodialysis (CVVHD)
Strong fit — clear ROI and a fast path to value.
End user70 fit
Continuous Venovenous Hemodiafiltration (CVVHDF)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Modality in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Product Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel26%
Digital / self-serve21%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Modality leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Continuous Renal Replacement Therapy Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified21%
Evaluation15%
Closed-won7%
$16.8KCAC
$73KLTV
4.4:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Continuous Renal Replacement Therapy Market is a resilient opportunity — $2.32B by 2033, compounding at 5.0%.
TAM · 2025$1.57Btoday
TAM · 2033$2.32Bforecast
CAGR5.0%2027–2033
Cumulative$17.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.32BTotal addressable market
SAM$957MServiceable available market
SOM$204MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.0% CAGR
Demand compounds through 2033, outpacing GDP across Modality.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Modality moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.32BLarge & growingTAM by 2033 at 5.0% CAGR
$957MServiceable nowreachable with today’s model
$204MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.81BBear3.3% CAGR
$2.32BBase5.0% CAGR
$2.98BBull6.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Product Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Continuous Renal Replacement Therapy Market — a $8.97B market by 2033. Plan: grow share from 10.8% to 16.9%.
Market size · 2033$8.97Btotal addressable
Market CAGR9.8%2027–2033
Target share16.9%from 10.8% today
Revenue ambition$1.52Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.8% | 16.9% | Behind |
| Revenue | $888M | $1.52B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 31.9% | 45.3% | Behind |
| Customer retention | 86.3% | 93.5% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Modality
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Product Type capability
A defensible second engine — invest in Product Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Modality share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Product Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $175M capacity & capability investment
- Greenlight bolt-on M&A in Product Type
- Authorise North America expansion plan
- Fund R&D program for Modality leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossBehind
- Input-cost & supply riskAhead
- Regulatory / policy changeBehind
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Continuous Renal Replacement Therapy Market conversation — a $10.5B market you can size, segment and defend in minutes.
Market size · 2033$10.5Btotal opportunity
Growth9.3%CAGR to 2033
Addressable buyers1,461+accounts in scope
Typical ROI5.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Modality
Goal Grow share in Modality
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.4×return on cost, year one
< 2 mopayback period
$97K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Baxter International Inc.Fresenius Medical Care AG & Co. KGaAB. Braun Melsungen AGNipro CorporationAsahi Kasei CorporationNxStage MedicalInc. (a Fresenius Medical Care company)Medtronic plc+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Continuous Renal Replacement Therapy Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Continuous Renal Replacement Therapy Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Drug for Ulcerative Colitis Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportOral and Topical Anaesthetics Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportSex Hormones Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportBreathing Disorders & Treatment Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportBone Graft Substitute Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportBioidentical Hormones Market
Market size, share, segmentation and regional forecast.
$1.4B market · 2025 base year
View reportAntihistamine Drugs Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportAntihelminthics Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportAntidiuretic Drugs Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportDPP IV Inhibitors (DPP-4 Inhibitors) Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportAnti-Neoplastic Agents Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportMineral Supplements Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.